Media Contact: mediarelations@atonrx.com


Click on a link to view a PDF of the full press release.


May 6, 2010
Aton Pharma, Inc. Acquisition

May 3, 2010
ARVO Poster: Study of Lacrisert^® Dry Eye Insert

April 26, 2010
Aton Pharma Acquires Parkinson's Drug LODOSYN^® (carbidopa)

April 7, 2010
Study of Lacrisert^® (hydroxypropyl cellulose ophthalmic) Dry Eye Insert at World Cornea Congress

March 4, 2010
Frost & Sullivan Recognizes TIMOPTIC^® (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma

August 19, 2009
Aton Pharma Launches Expanded Distribution and Marketing for Preservative-Free TIMOPTIC^® in OCUDOSE^®

August 19, 2009
Study of Lacrisert^® Dry Eye Insert Published in The Ocular Surface

May 5, 2009
Large Study of Lacrisert^® Dry Eye Insert Patients Experience Significant Improvement in Ocular Surface Disease and Quality of Life

April 6, 2009
Ophthalmologists Cite Benefits of Preservative-Free Medications on Ocular Comfort and Quality of Life

February 25, 2009
Aton Pharma Acquires U.S. TIMOPTIC^® Product Line from Merck & Co., Inc.

November 10, 2008
Aton Pharma Announces Results of a Recent Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in the Treatment of Moderate to Severe Dry Eye

May 19, 2008
Aton Pharma Announces Distribution Partnership in the Asia Pacific Region

May 12, 2008
Aton Pharma Announces Distribution Partnership in Brazil

February 18, 2008
Aton Pharma Announces the Appointment of Dr. Fred Eshelman to Management Board

January 23, 2008
Aton Pharma Introduces Expanded Distribution of Lacrisert^® (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye

April 30, 2007
Aton, MAP International Provide Medicine Where Most Needed

January 1, 2007
Aton Pharma, Inc. Announces Partnership With The National Organization for Rare Disorders (NORD)

October 12, 2006
Aton Pharma, Inc Acquired by Princeton Pharma Holdings, LLC